OTTAWA, Dec. 12 /CNW Telbec/ - The Canadian Agency for Drugs and
Technologies in Health (CADTH) today expressed its appreciation for the
observations and recommendations made by the House of Commons Standing
Committee on Health in its report tabled this afternoon: Prescription Drugs
Part I - Common Drug Review: An F/P/T Process.
"The one unifying theme throughout the committee presentations was that
the demands placed on Canada's publicly funded health system are enormous,"
said John Wright, then Co-chair of the Conference of Deputy Ministers of
Health (CDM), the owners of CADTH and the Common Drug Review (CDR) program, in
his appearance before the committee. "Achieving the balance of optimized care,
accessibility, equity, affordability and sustainability for all Canadians is
every government's goal," continued Mr. Wright. "That is precisely why we
welcome the report's suggestions and recommendations and look forward to the
federal government's response to the report."
"Many of the report's findings are consistent with initiatives already
underway at CADTH, but there is always room for improvement," noted Dr. Jill
Sanders, CADTH's President and Chief Executive Officer.
"Since its inception, the CDR has successfully delivered on its original
mandate of conducting objective, rigorous and timely reviews of new drugs, and
providing formulary listing recommendations to Canada's public drug plans,"
said Dr. Sanders. "Throughout the short history of the CDR, we have
continuously demonstrated the ability to evolve to meet new challenges on
behalf of Canadians."
One significant change, for the CDR, was the appointment in October 2006
of two public members with full voting rights to its Canadian Expert Drug
Advisory Committee (CEDAC). CDR will continue to set the benchmark for
transparency in drug reviews by publicly releasing in the future: plain
language versions of CDR recommendations; overviews of CDR reviews; and
summaries of drug discussions at CEDAC meetings.
"These are just a few of the initiatives CADTH intends to carry out,"
said Dr. Sanders. "In response to the Standing Committee report, we will
undertake a review of the benefits and implications of the recommendations,
and bring them to the CADTH Board of Directors for consideration. CADTH will
also assist the federal government in preparing their response to the Standing
The Canadian Agency for Drugs and Technologies in Health (CADTH) is a
national body that provides Canada's federal, provincial, and territorial
health care decision makers with credible, impartial advice and evidence-based
information about the effectiveness and efficiency of drugs and other health
technologies. CADTH is governed by a 13-member jurisdictional Board of
Directors that reports to the Conference of Federal, Provincial and
Territorial Deputy Ministers of Health.
For further information:
For further information: John Yan, Director, Communications, Canadian
Agency for Drugs and Technologies in Health, (613) 226-2553, ext. 276,
email@example.com, www.cadth.ca; Sandy Fox, Senior Communications Advisor, Common
Drug Review, Canadian Agency for Drugs and Technologies in Health, (613)
226-2553, ext. 233, firstname.lastname@example.org, www.cadth.ca